311 – 320 of 324
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 1997
-
Mark
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
(
- Contribution to journal › Article
-
Mark
Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study
(
- Contribution to journal › Article
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
-
Mark
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
(
- Contribution to journal › Article
- 1996
-
Mark
Antitrombin III-koncentrat söker sin roll i terapin. Var försiktig och invänta studieresultat!
(
- Contribution to journal › Article
-
Mark
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
(
- Contribution to journal › Article
- 1995
-
Mark
Resistens mot aktiverat protein C. Vanlig genetisk riskfaktor för venös trombos
(
- Contribution to journal › Article
- 1994
-
Mark
Myocardial infarction associated with homozygous resistance to activated protein C
(
- Contribution to journal › Letter
-
Mark
Prophylactic treatment of severe hemophilia A and B can prevent joint disability
(
- Contribution to journal › Article
- 1992
-
Mark
Laparoscopic cholecystectomy in a patient with hemophilia B
(
- Contribution to journal › Article